About Hzymes Biotech
Hzymes Biotechnology Co., Ltd., founded in 2015, is a high-tech enterprise specializing in R&D, production, application, and technical services for core raw materials for biomedicine and in vitro diagnostics. The company maintains an extensive business network with marketing and R&D centers in Shanghai, Wuhan, and Yichang.
Technologically, the company has established specialized platforms including enzyme gene mining & characterization, enzyme molecular engineering, high-throughput screening, organic synthesis, synthetic biology, and antigen/antibody development. Leveraging these platforms, it has developed hundreds of core raw materials for biomedicine, vaccine production, and in vitro diagnostics.
Hzymes Biotech operates a pharmaceutical-grade specialty enzyme production system featuring ultra-large-scale capacity and ultra-high equipment standards in manufacturing. Currently serving over 2,400 biomedicine, vaccine, and IVD reagent manufacturers worldwide, its products are exported to more than 40 countries and regions. The company collaborates closely with academic institutions such as Shanghai Jiao Tong University, Shanghai Institute of Laboratory Medicine, and Suzhou Institute of Biomedical Engineering and Technology (CAS), integrating cutting-edge life science technologies to accelerate the commercialization of research achievements.
Guided by its mission to "innovate foundational technologies to benefit life" and core values of "Client-Centric Approach, Innovation, Excellence, Accountability, and Win-Win Collaboration," Hzymes Biotech continues to expand its product portfolio and advance toward its vision of becoming "a global leader in core biotechnologies."
Technologically, the company has established specialized platforms including enzyme gene mining & characterization, enzyme molecular engineering, high-throughput screening, organic synthesis, synthetic biology, and antigen/antibody development. Leveraging these platforms, it has developed hundreds of core raw materials for biomedicine, vaccine production, and in vitro diagnostics.
Hzymes Biotech operates a pharmaceutical-grade specialty enzyme production system featuring ultra-large-scale capacity and ultra-high equipment standards in manufacturing. Currently serving over 2,400 biomedicine, vaccine, and IVD reagent manufacturers worldwide, its products are exported to more than 40 countries and regions. The company collaborates closely with academic institutions such as Shanghai Jiao Tong University, Shanghai Institute of Laboratory Medicine, and Suzhou Institute of Biomedical Engineering and Technology (CAS), integrating cutting-edge life science technologies to accelerate the commercialization of research achievements.
Guided by its mission to "innovate foundational technologies to benefit life" and core values of "Client-Centric Approach, Innovation, Excellence, Accountability, and Win-Win Collaboration," Hzymes Biotech continues to expand its product portfolio and advance toward its vision of becoming "a global leader in core biotechnologies."
Category Press Releases